Skip to content

A second daily pill for PrEP was approved in 2019, using a drug combination of tenofovir and alafenamide and emtricitabine, known as F/TAF, brand name Descovy. To date its approval is restricted to men who have sex with men and transgender women. Data in cisgender women is not yet available, but is expected from an ongoing trial known as Purpose 1, which is also testing the efficacy of an injectable PrEP using the drug lenacapavir.


Prevention options that mitigate or eliminate barriers to access are essential. Key populations, including men who have sex with men (MSM), transgender women (TGW), female sex workers (FSW), and adolescent girls and young women (AGYW) need effective options that work and fit into their lives. Each HIV prevention option has unique characteristics, and individuals may prefer a particular PrEP method for any number of reasons. Ensuring informed choice is key.

Oral PrEP is another strategy to help reduce HIV risk. For some people it will be the right one; for others, it will be injectable cabotegravir for PrEP or the dapivirine vaginal ring (the PrEP ring); for another, a non ARV-based approach will be right. Research and development have created new options; now advocacy is needed to make them viable choices for people who need and want them.

Clinical Trials Evidence

The 2019 US FDA decision was based on the results of the phase 3 DISCOVER trial, which compared the safety and efficacy of TDF/FTC to F/TAF in HIV-negative participants, and found F/TAF to be as effective.

Findings from National Introduction and Scale-Up

Visit AVAC’s Global PrEP Tracker for the latest updates to PrEP uptake by country.